Cediranib (RECENTIN (development name))
Targeted Therapy
Description
Cediranib (AZD2171) is an oral small molecule tyrosine kinase inhibitor that targets multiple vascular endothelial growth factor receptors (VEGFRs). In colorectal cancer treatment, cediranib has been evaluated as an anti-angiogenic agent in combination with standard chemotherapy regimens including FOLFOX for both first-line and second-line treatment of metastatic disease. The drug works by blocking tumor blood vessel formation and growth, potentially enhancing the effectiveness of cytotoxic chemotherapy.
Mechanism of Action
Cediranib selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3 tyrosine kinases, which are critical signaling pathways for angiogenesis and lymphangiogenesis. By blocking these receptors, the drug prevents the formation of new blood vessels that tumors require for growth and metastasis, effectively starving the tumor of nutrients and oxygen while also normalizing existing tumor vasculature.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | RECENTIN (development name) |
| Category | Targeted Therapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 7 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.